Summary
The discovery of cyclosporin in 1972 was a major advance in immunopharmacology. Cyclosporin specifically modifies the immune response, without lymphotoxicity, and inhibits graft rejection.
Cyclosporin is a cyclic peptide isolated from the fungus Tolypocladium inflatum. It acts principally on T lymphocytes by binding to cyclophilin, a member of the family of isomerases known as the immunophilins. Other immunosuppressive agents such as tacrolimus (FK-506) and sirolimus (rapamycin) also act by binding to immunophilins; the combination of cyclosporin and sirolimus has been shown to have synergistic properties. Cyclosporin has anti-inflammatory effects in chronic inflammation, and at high doses prevents chronic rejection.
The future aims of immunosuppressive therapy should be to (i) induce allograft tolerance, (ii) permit discontinuation of corticosteroids, (iii) reduce adverse effects, (iv) avoid long term immunosuppression with high doses of agents, and (v) allow treatment of chronic rejection. Experimental studies with combinations of cyclosporin and other agents appear promising. Future immunosuppressive strategies will probably use successive combinations of synergistic drugs at low doses, allowing induction of allograft tolerance without serious adverse effects or the need for life-long therapy.
Similar content being viewed by others
Références
Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmune). Transplant Proc 1991; 23: 1867–74
Borel JF, Di Padova F, Mason J, et al. Pharmacology of cyclosporine (Sandimmune). Pharmacol Rev 1989; 41: 239–434
Borel JF, Baumann G, Chapman I, et al. In vivo pharmacological effects of cyclosporine and some analogues. Adv Pharmacol 1996; 35: 115–246
Baumann G, Borel JF. Mécanismes moléculaires de l’ action des agents immunosuppresseurs. Méd Sci 1992; 8: 366–71
Borel JF, Feutren G, Baumann G, et al. Cyclosporin and some new immunosuppressive drugs in the treatment of autoimmune diseases. In: Lydyard PM, Brostoff J, editors. Autoimmune disease: aetiopathogenesis, diagnosis and treatment. Oxford: Blackwell Science, 1994: 169–217
Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137–41
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Borel, JF. La ciclosporine en immunologie: passé, présent et avenir. BioDrugs 8 (Suppl 1), 1–3 (1997). https://doi.org/10.2165/00063030-199700081-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199700081-00004